Citations

Objectives: Evidence is limited related to the effects of autograft type on functional performance during gait lab-based functional testing after ACL reconstruction (ACLR), especially the quadriceps autograft. The goal of this study was to compare biomechanical outcomes as measured by 3D motion analysis during the drop vertical test between quadriceps autograft with bone block (QB), quadriceps autograft without bone block (Q), hamstring autograft (HS), and bone-patellar tendon-bone autograft (BTB) six-months postoperatively in an adolescent population. We hypothesized that the quadriceps groups would demonstrate decreased knee extension moments as compared to the hamstring autograft group without other significant differences. Methods: Patients aged 8-18 years who underwent primary ACLR were included. Patients with previous history of ipsilateral knee surgery were excluded. Kinematic and kinetic data collected during a drop vertical jump test in a formal gait lab using a computerized video-based system (Motion Analysis Corp. CORTEX software) was collected six months after ACLR and compared to the uninjured contralateral limb. The Kruskal Wallis test and subsequent pairwise comparisons were carried out for each studied parameter. Primary outcomes included transverse plane hip power, hip internal rotation moment, knee valgus angles, and knee extensor moments between the graft types. Secondary outcomes included hip abduction moment, knee valgus moment, and knee external rotation moment. Results: A total of 155 subjects’ charts were included for review, with 54, 40, 35, and 26 subjects in the HS, QB, Q, and BTB groups respectively. There were no significant differences in terms of age, sex, or affected leg (p > 0.1973). Athletic activity for each subject was also noted when appropriate, including soccer (37), basketball (34), and American football (30). The QB group had smaller knee extension moments maximums (-0.97 N*m/kg vs. -0.35 N*m/kg, p = 0.0323) and smaller knee extension moment averages (-0.12 N*m/kg vs. -0.03 N*m/kg, p = 0.0265) as compared to the HS group. The Q group demonstrated smaller knee extension moment averages (-0.13 N*m/kg vs. -0.03 N*m/kg, p = 0.459) as compared to the HS group. Analysis of secondary outcomes revealed that the HS group demonstrated larger knee valgus moments at initial contact (0.28 N*m/kg vs -0.35 N*m/kg, p = 0.0254) as compared to the Q group. The HS group demonstrated significantly larger hip adduction moment maximums (0.30 N*m/kg vs -0.04 N*m/kg, p = 0.0426) and smaller knee external rotation moment averages (-0.02 N*m/kg vs 0.02 N*m/kg, p = 0.0206) as compared to the QB group. No other secondary outcomes were statistically significant between any of the groups. Conclusions: The findings of this study suggest that the quadriceps autograft may confer improved knee coronal plane biomechanics in regard to ACL reinjury rates when compared to a hamstring autograft at 6 months after ACLR in adolescent patients performing a drop vertical jump. The hamstring autograft group was significantly associated with larger knee valgus moments at initial contact as compared to the quadriceps autograft without bone block and significantly larger hip adduction moments compared to the quadriceps autograft with bone block. Both quadriceps grafts were shown to demonstrate significantly decreased knee extension moments as compared to a hamstring autograft. Further long-term clinical studies may be useful in determining whether the apparent biomechanical differences seen between autograft types are correlated with reinjury rates.

Objectives: Meniscus injuries remain a common source of morbidity in patients over the age of 40. Historically, meniscus injuries in this age group have been treated non-operatively or with surgical management limited to debridement procedures. There is strong evidence for repair over meniscectomy in younger patients, however literature remains sparce regarding repair outcomes and re-operation rates for patients over the age of 40. The objectives of this study were to document patient reported outcomes, complications, and re-operation rates for meniscus repairs in patients above the age of 40 and determine what patient demographics or injury characteristics correlated with reoperation. Methods: A retrospective chart review was conducted at a single academic institution after obtaining IRB approval. An initial query of patients over the age of 40, was performed via the CPT code 29882. Inclusion criteria consisted of patient age greater than 40 at time of initial meniscal repair. Exclusion criteria consisted of prior surgery in the ipsilateral knee, meniscal root repair, septic arthritis postoperatively, and any form of knee trauma postoperatively. Patients that met inclusion criteria were chart reviewed for relevant data including demographic information, comorbidities, surgical procedure information such as type of implant used, laterality of meniscus tear, type of tear and pattern, and revision/re-operation data. Patients were then contacted to answer full 100-point KOOS (Knee Injury and Osteoarthritis Outcome Score) questionnaires. Results: 413 total patients met inclusion criteria. The average age at time of surgery was 46 years (IQR, 43-51), and 214 patients were female (51.8%). KOOS scores were reported at a median follow-up of 24-months (IQR, 3-62). Median symptom, pain, activity of daily living (ADL), sport, and quality of life (QoL) subscales were reported as 78.6 (IQR, 60.7-92.9), 87.5 (IQR, 69.4-97.2), 94.1 (IQR, 82-100), 80.0 (IQR, 55-95), and 68.8 (IQR, 40.6-81.3), respectively. A total of 74 patients underwent reoperation (17.8%). There was no significant difference in reoperation rates when stratified by age group (40-49, 50-59, 60-69) (p=0.515). Reoperation rates were not affected by type of implant used for initial meniscus repair (Fast-fix anchor, Omnispan meniscal anchor, Meniscal cinch implant, Fiberwire, MaxBraid suture, Ethibond suture, PDS suture or Bionics meniscal arrow) (p>0.7). Average number of all-inside anchors used for repair was 2 (IQR, 2-3) and did not correlate with reoperation (p=0.49). Location of initial meniscus tear (body or posterior horn) and tear pattern did not correlate with reoperation rates (p>0.36, p>0.28 respectively). A total of 47 patients complained of postoperative stiffness, of which 28 (6.7%) underwent lysis of adhesions and/or arthroscopic debridement (p=.042). Twenty-five patients sustained a meniscal re-tear or injury, of which 17 underwent reoperation with partial or total meniscectomy. Of the total patient cohort, only seven patients ultimately went on to require ipsilateral total knee arthroplasty (1.6%). Conclusions: Patients over the age of 40 who underwent meniscus repair showed favorable reported outcomes at a mean 2-year follow-up. Reoperation rates were associated with postoperative stiffness and repeat injury. Re-operation rates in patients over 40 are comparable to reported rates of younger patients who undergo meniscus repair.

Objectives: ACL reconstruction using hamstring autograft (HA) has been found to have a high re-tear rate in high risk patients including those with a Pivot shift of 2 or higher and those with generalized ligamentous laxity (GLL). Because of this, the use of lateral extra-articular tenodesis (LET) has gained traction in the sports community. Several studies have shown lower ACL graft re-tears with the addition of LET and is felt by many to be necessary when using a HA in high risk patients. However, no study has compared hamstring autograft + LET versus other graft types. The purpose of our study was to compare the surgical outcomes of HA+LET vs an all-soft-tissue quadriceps autograft (QA) without LET. We hypothesized that a QA would lead to similar graft re-tear and rotational instability rates as HA+LET. Methods: This retrospective study compared high risk patients including those with a Pivot shift of 2 or more and GLL undergoing ACL reconstruction with either a HA, HA+LET and QA. In this study, GLL was defined as patients with a Beighton score of 4 or more. Patients were included in the study if they were undergoing a primary ACL reconstruction with either hamstring autograft (HA group), hamstring autograft with extra-articular tenodesis (HA+LET group) or all-soft-tissue quadriceps autograft (QA group) and no other procedures other than meniscal work. All surgeries were performed by the senior surgeon and followed the same rehabilitation protocol after surgery regardless of what type of graft was used during the surgery. Graft choice was dependent on the when during the study the procedure was performed. Early in the study period, HA were used on most patients regardless of whether they were high risk or not. Later, HA+LET was performed due to emerging studies showing higher failure rates in high risk patients undergoing HA alone compared to those undergoing HA+LET. Finally, the senior author transitioned to using QA for most cases. Patient reported outcomes (PROs) were obtained on each patient preoperatively, 3,6,12 and 24-months after surgery. The PROs used in this study included the International Knee Documentation Committee (IKDC) and Lysholm scores. Clinical failure was defined by a patient who had a graft re-tear or those with a residual pivot shift of 2 or more after surgery. Pivot shift was tested for at the 6,12 and 24-month follow up. Other complications associated with the procedure were documented. Results: A total of 166 high risk patients underwent ACL reconstruction over the 7 year study period. There were 63 patients in the HA group, 47 in the HA+LET and 56 in the QA group. The demographics between the three groups was similar with an overall age of the patients in the study being 17.8 years. The mean Beighton score was 3.2 for the group with 24% of the population having GLL. The overall rate of Grade 2 or higher pivot was 82%. There was no difference between the groups with regards to percentage GLL or 2+pivot shift. All three groups had a higher percentage of women than men (HA group 66%; HA+LET group 62% and QA group 56%), but there was no significant difference between the groups. The QA group had a significantly larger graft diameter (9.6mm) compared to the HA group (7.9mm) and the HA+LET group (8.1mm) (p<.001). The number of meniscal repair and partial meniscectomy was similar between all three groups with 21.1% of the population undergoing meniscectomy and 48% of the entire population undergoing meniscal repair. The study was made up of 68.4% athletes for the HA group, 62.4% for the HA+LET and 72.6% for the QA group (p=.32). A significant increase in both IKDC and Lysholm scores were seen at every timepoint compared to preoperative levels. There was no difference between the three groups at any time point for either the IKDC and Lysholm scores. The preoperative IKDC score for the HA group increased from 51.7 to 90.3 at the 2-year follow-up. The HA+LET IKDC scores increased from 53.1 preoperatively to 88.4 at the 2-year follow-up. The QA group had IKDC scores of 49.8 pre op and 90.6 at 2 years. The Lysholm scores increased from 53 to 91.9, 54.8 to 89.4 and 51.9 to 92.6 preoperatively to the 2-year follow-up for the HA, HA+LET and QA groups respectively. The graft re-tear rate of the HA group was significantly higher than the HA+LET and QA groups (14.3%, 2.1% and 1.8% respectively). Residual pivot shift of 2 or more was found in 36.5% of the HA group, 14.9% in the HA+LET group and 19.6% in the QA group. The residual pivot shift in the HA group was significantly higher than the HA+LET and QA groups, but no difference was identified between the HA+LET and QA groups. Return to sport (RTS) was similar between the three groups with 80% of athletes returning to sport with HA grafts, 81% with HA+LET and 86% with QA grafts. The use of a QA in this high-risk population lead to a significantly faster RTS (8.6 months) compared to the HA and HA+LET groups; however, the addition of a LET did not lead to a shorter time to return to sport (10.7 months for the HA group and 11.7 months for the HA+LET group). There was no difference between the three groups for contralateral ACL tears, arthrofibrosis or infection. Conclusions: The use of an all-soft-tissue QA or the addition of an LET to a HA both lead to significant decreases in graft re-tear rate and residual pivot shifts of 2 or greater compared to a HA graft alone in high risk patients undergoing primary ACL reconstruction. However, the use of QA and LET do not improve the patient reported outcome scores at 2-year follow up compared to HA alone. RTS was significantly faster with QA compared to the HA and HA+LET; however, the addition of an LET to a HA did not increase the rate to which an athlete was able to return to play. In conclusion, high risk patients including those with GLL and pivot shifts greater than 2 should undergo ACL reconstruction with either a quadriceps autograft or have a LET added to a hamstring autograft.

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. ARST1321 was a phase II study designed to compare the near complete pathologic response rate after preoperative chemoradiation with/without pazopanib in children and adults with intermediate-/high-risk chemotherapy-sensitive body wall/extremity non-Rhabdomyosarcoma Soft Tissue Sarcoma (ClinicalTrials.gov identifier: NCT02180867 ). Enrollment was stopped early following a predetermined interim analysis that found the rate of near complete pathologic response to be significantly greater with the addition of pazopanib. As a planned secondary aim of the study, the outcome data for this cohort were analyzed. Eight-five eligible patients were randomly assigned to receive (regimen A) or not receive (regimen B) pazopanib in combination with ifosfamide and doxorubicin + preoperative radiotherapy followed by primary resection at week 13 and then further chemotherapy at week 25. As of December 31, 2021, at a median survivor follow-up of 3.3 years (range, 0.1-5.8 years), the 3-year event-free survival for all patients in the intent-to-treat analysis was 52.5% (95% CI, 34.8 to 70.2) for regimen A and 50.6% (95% CI, 32 to 69.2) for regimen B ( P = .8677, log-rank test); the 3-year overall survival was 75.7% (95% CI, 59.7 to 91.7) for regimen A and 65.4% (95% CI, 48.1 to 82.7) for regimen B ( P = .1919, log-rank test). Although the rate of near complete pathologic response was significantly greater with the addition of pazopanib, outcomes were not statistically significantly different between the two regimens.

Abstract Rationale In addition to rare genetic variants and the MUC5B locus, common genetic variants contribute to idiopathic pulmonary fibrosis (IPF) risk. The predictive power of common variants outside the MUC5B locus for IPF and interstitial lung abnormalities (ILAs) is unknown. Objectives We tested the predictive value of IPF polygenic risk scores (PRSs) with and without the MUC5B region on IPF, ILA, and ILA progression. Methods We developed PRSs that included (PRS-M5B) and excluded (PRS-NO-M5B) the MUC5B region (500-kb window around rs35705950-T) using an IPF genome-wide association study. We assessed PRS associations with area under the receiver operating characteristic curve (AUC) metrics for IPF, ILA, and ILA progression. Measurements and Main Results We included 14,650 participants (1,970 IPF; 1,068 ILA) from six multi-ancestry population-based and case–control cohorts. In cases excluded from genome-wide association study, the PRS-M5B (odds ratio [OR] per SD of the score, 3.1; P = 7.1 × 10−95) and PRS-NO-M5B (OR per SD, 2.8; P = 2.5 × 10−87) were associated with IPF. Participants in the top PRS-NO-M5B quintile had ∼sevenfold odds for IPF compared with those in the first quintile. A clinical model predicted IPF (AUC, 0.61); rs35705950-T and PRS-NO-M5B demonstrated higher AUCs (0.73 and 0.7, respectively), and adding both genetic predictors to a clinical model yielded the highest performance (AUC, 0.81). The PRS-NO-M5B was associated with ILA (OR, 1.25) and ILA progression (OR, 1.16) in European ancestry participants. Conclusions A common genetic variant risk score complements the MUC5B variant to identify individuals at high risk of interstitial lung abnormalities and pulmonary fibrosis.

Abstract Rationale Global Lung Function Initiative (GLI) Global spirometry reference equations were recently derived to offer a “race-neutral” interpretation option. The impact of transitioning from the race-specific GLI-2012 to the GLI Global reference equations is unknown. Objectives Describe the direction and magnitude of changes in predicted lung function measurements in a population of diverse race and ethnicity using GLI Global in place of GLI-2012 reference equations. Methods In this multicenter cross-sectional study using a large pulmonary function laboratory database, 109,447 spirometry tests were reanalyzed using GLI Global reference equations and compared with the existing GLI-2012 standard, stratified by self-reported race and ethnicity. Measurements and Main Results Mean FEV1 and FVC percent predicted increased in the White and Northeast Asian groups and decreased in the Black, Southeast Asian, and mixed/other race groups. The prevalence of obstruction increased by 9.7% in the White group, and prevalences of possible restriction increased by 51.1% and 37.1% in the Black and Southeast Asian groups, respectively. Using GLI Global in a population with equal representation of all five race and ethnicity groups altered the interpretation category for 10.2% of spirometry tests. Subjects who self-identified as Black were the only group with a relative increase in the frequency of abnormal spirometry test results (32.9%). Conclusions The use of GLI Global reference equations will significantly impact spirometry interpretation. Although GLI Global offers an innovative approach to transition from race-specific reference equations, it is important to recognize the continued need to place these data within an appropriate clinical context.